Organic & Biomolecular Chemistry · 2013 · 33 citations · 22 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoverySynthetic Medicinal ChemistryApoptosis PharmacologyEnzyme InhibitionOncology PharmacologyCancer Cell Proliferation InhibitionGrowth Inhibition AssaysMedicinal Chemistry ApplicationsQuinoline ChemistryQuinoxaline ChemistryQuinoxaline SynthesisTherapeutic Growth Inhibition
A series of 1,3-disubstituted pyrrolo[2,3-b]quinoxalines has been designed for the potential inhibition of PDE4 without inhibiting luciferase. A ligand/PTC (phase transfer catalyst) free intramolecular Heck cyclization strategy was used to prepare these compounds, some of which showed significant inhibition of PDE4B (IC50≈ 5-14 μM) and growth inhibition of oral cancer cells (CAL 27) but not inhibition of luciferase in vitro. They also showed acceptable safety profiles but no apoptosis in zebrafish embryos.
22
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
Larry Rubinstein, Robert H. Shoemaker, Kenneth D. Paull et al. · JNCI Journal of the National Cancer Institute · 1990 · 931 citations
Medicine, Oncology, Pharmacology +14